Post by GSK

4,799,957 followers

#News for #Investors and #Media: Today we announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome, a rare and severe hemato-inflammatory disease, where there is a high unmet need. Learn more: https://gsk.to/3S44Vnp

Post content

Video Content